RLAY Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Loading...
Buy (speculative biotech). Despite a weak near-term technical setup, RLAY is trading near support (~7.14) after a pullback, while sentiment data (very call-heavy options flow, hedge-fund buying surge) and fresh Wall Street upgrades with $13–$14 targets create a favorable near-term risk/reward for an impatient buyer looking for upside now rather than waiting for an ideal entry. The main bull case is event-driven (pipeline/readouts and positioning vs competitors), so the upside can materialize quickly if momentum returns.
Trend/price action: RLAY is $7.55 (-3.11% regular session) with a small pre-market rebound (+1.30%), suggesting dip-buying attempts but not a confirmed reversal. Momentum: MACD histogram is negative (-0.0269) and expanding lower, which signals bearish momentum still in control. RSI: RSI(6) ~42, neutral-to-weak (not oversold), implying room for further downside before a natural technical snapback becomes more likely. Moving averages: Converging MAs often precede a larger move; direction is not confirmed, but current momentum skews downside. Key levels: Pivot 7.757 (price below pivot = near-term bearish). Support S1 7.136 then S2 6.753; Resistance R1 8.378 then R2 8.761. A hold above ~7.14 increases the odds of a bounce back toward 7.76–8.38. Pattern-based probabilities (given): Similar-pattern stats imply modest positive drift (next day +1.68%, next week +3.04%, next month +3.49%), supporting a tactical buy near support.
Intellectia Proprietary Trading Signals
Wall Street upgrades and higher price targets: Oppenheimer upgraded to Outperform with a $14 PT (2026-01-26); Wells Fargo upgraded to Overweight with a $13 PT (2025-12-12), reinforcing renewed institutional interest.
Event-driven upside narrative: Oppenheimer frames a potential tailwind for Relay’s zovegalisib if competitor gedatolisib data underwhelms, creating a relative-value catalyst.
Hedge fund accumulation: Reported hedge-fund buying amount up ~352.49% over the last quarter, often supportive of sustained bids.
Call-skewed options positioning and elevated options activity: suggests traders are leaning bullish into upcoming catalysts.
Upcoming earnings date (2026-02-24 after hours) can act as a volatility/catalyst window, often creating pre-event positioning flows.
Weak technical momentum: Negative and worsening MACD histogram; price below pivot (7.
keeps near-term trend fragile.
Binary/competitive thesis risk: The Oppenheimer bull case is tied to competitor outcomes and comparative efficacy; unfavorable read-throughs can hurt sentiment quickly.
Cash-burn profile typical of pre-revenue biotech: continued losses can pressure shares if financing concerns rise.
Earnings/event volatility: With a catalyst calendar approaching, downside gaps are possible if updates disappoint.
Latest reported quarter: 2025/Q3. Revenue: $0 (no growth; still pre-commercial). Profitability: Net income -$74.15M (loss widened ~15.84% YoY). EPS: -$0.43 (down ~31.75% YoY). Interpretation: Financials show increasing losses without revenue offset; the stock is driven primarily by pipeline progress and expectations rather than current operating performance. Next earnings: QDEC 2025 earnings scheduled 2026-02-24 (after hours), with EPS estimate around -0.38.
Recent trend: Ratings have improved meaningfully with two notable upgrades in the last ~6–8 weeks.
